JP MORGAN 2015: Bristol-Myers oncology head boasts PD-1 promise, partners
This article was originally published in Scrip
Executive Summary
"The strategy of being able to use immune-oncology to improve outcomes is being realized," Bristol-Myers Squibb head of oncology development Michael Giordano told Scrip on 12 January during the 33rd Annual JP Morgan Healthcare Conference in San Francisco.